Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients

Anadys Pharmaceuticals, Inc. announced today that it has initiated the planned Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin.

Published
05 January 2011
From
PR Newswire
Hepatitis Experts Create Roadmap for Accelerating the Development of Targeted Therapies for Hepatitis C Virus

To improve the care for individuals infected with the hepatitis C virus, a major health problem and a leading cause of chronic liver disease around the world, nearly 200 international hepatitis experts have taken an important step in escalating the introduction of a new class oftargeted therapies for HCV - direct-acting antivirals (DAAs).

Published
15 December 2010
From
Forum for Collaborative HIV Research
Medivir AB reports positive interim data on Phase 2b ASPIRE study for hepatitis C

The results demonstrate the potent and consistent antiviral efficacy of TMC435 in patients who had failed earlier treatment with peg-IFN and ribavarin (standard of care).

Published
18 November 2010
From
Medical News Today
Rapid hepatitis C antibody tests show wide range of results

The first generation of rapid screening tests for the hepatitis C virus (HCV) antibody, which use blood and oral fluids, underwent field testing in September at 4 sites. The tests had considerable variation in performance across the 4 test sites, with wide ranges in sensitivity, specificity, positive predictive value, and negative predictive value.

Published
17 November 2010
From
Medscape
Liver Cancer Survival Similar in HIV-Positive and HIV-Negative People

Three-year survival rates after a diagnosis of hepatocellular carcinoma (liver cancer) are similar between people living with HIV and HIV-negative people, according to a study presented at the American Association for the Study of Liver Diseases being held October 29 to November 2 in Boston.

Published
09 November 2010
From
AIDSMeds
Early analysis finds good outcomes with once-daily dosing of HCV protease inhibitor TMC435

Tibotec's investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, TMC435, produced good viral suppression in previously untreated genotype 1 patients when taken once-daily in combination with pegylated interferon plus ribavirin for 12 or 24 weeks, according to interim results from the PILLAR study.

Published
08 November 2010
From
HIVandhepatitis.com
From podium to practice: Updates in HCV treatment

CCO official conference coverage of the 2010 Annual Meeting of the American Association for the Study of Liver Diseases.

Published
08 November 2010
From
Clinical Care Options (registration required)
Isentress Might Reduce Risk of a “Fatty” Liver From Protease Inhibitors

A new laboratory study suggests that the integrase inhibitor Isentress (raltegravir) could prevent the accumulation of excess fat in the liver (steatosis) that results from protease inhibitor (PI) therapy. These data were presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases, held October 29 to November 2 in Boston.

Published
04 November 2010
From
Poz magazine news
Hepatitis C researcher arrested on insider trading charges

A prominent French doctor has been arrested on criminal fraud charges that accused him of tipping off a hedge fund manager about setbacks in a clinical drug trial that had not yet been made public, federal authorities said Tuesday.

Published
03 November 2010
From
New York Times
AASLD: Anti-HCV drug boosts response rates

Combining the direct anti-viral agent telaprevir with standard hepatitis C care can sharply improve response rates and shorten the treatment period, researchers reported.

Published
03 November 2010
From
MedPage Today

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.